FNY Managed Accounts LLC acquired a new position in shares of Qiagen N.V. (NASDAQ:QGEN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,570 shares of the company’s stock, valued at approximately $103,000.
Other large investors also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. bought a new stake in shares of Qiagen N.V. during the first quarter worth about $114,000. Quadrant Capital Group LLC increased its stake in shares of Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares in the last quarter. Elkfork Partners LLC bought a new stake in shares of Qiagen N.V. during the fourth quarter worth about $180,000. Rehmann Capital Advisory Group acquired a new stake in Qiagen N.V. during the first quarter valued at $207,000. Finally, Prudential Financial Inc. acquired a new stake in Qiagen N.V. during the first quarter valued at $207,000. 61.04% of the stock is owned by institutional investors and hedge funds.
Shares of Qiagen N.V. (NASDAQ:QGEN) traded up 1.62% during midday trading on Wednesday, hitting $33.79. The stock had a trading volume of 158,872 shares. Qiagen N.V. has a one year low of $22.80 and a one year high of $35.26. The firm has a 50 day moving average price of $33.63 and a 200 day moving average price of $30.30. The stock has a market cap of $7.69 billion, a PE ratio of 93.86 and a beta of 1.15.
WARNING: This report was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/07/12/fny-managed-accounts-llc-invests-103000-in-qiagen-n-v-qgen-updated-updated.html.
Several analysts have recently weighed in on QGEN shares. TheStreet downgraded Qiagen N.V. from a “b-” rating to a “c” rating in a research report on Monday, April 24th. Zacks Investment Research downgraded Qiagen N.V. from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a report on Tuesday, May 2nd. Barclays PLC restated a “buy” rating and issued a $33.00 price objective on shares of Qiagen N.V. in a report on Monday, May 15th. Finally, Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a report on Monday, May 15th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $29.36.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.